Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | CSF1R | P07333 | 6/20 | 0.42 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7970274 | 0.87 | TLR7 (0.42) | PDE5ACSF1RALDH1A1HPGDRPS6KB1 | |
| SCHEMBL7973381 | 0.86 | TLR7 (0.46) | PDE5ACSF1REGFRALDH1A1HPGD | |
| SCHEMBL7960335 | 0.74 | CSF1R (0.47) | CSF1RALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL1223458 | 0.63 | PDE5A (0.43) | PDE5ACSF1REGFRALDH1A1RPS6KB1 | |
| SCHEMBL9379285 | 0.63 | PDE5A (0.52) | PDE5ACSF1RALDH1A1RPS6KB1METAP2 | |
| SCHEMBL12889093 | 0.63 | ALDH1A1 (0.54) | PDE5ACSF1RALDH1A1METAP2METAP1 | |
| SCHEMBL600149 | 0.62 | SLC29A1 (0.48) | ALDH1A1SMN1; SMN2TSHRKMT2APOLB | |
| SCHEMBL9760037 | 0.62 | TSHR (0.56) | ALDH1A1SMN1; SMN2TSHRKDM4EHTR1D | |
| SCHEMBL18485898 | 0.62 | RAB9A (0.54) | PDE5ACSF1RALDH1A1METAP2METAP1 | |
| Ethylene Glycol SCHEMBL8725210 | 0.62 | TSHR (0.81) | ALDH1A1TSHRKMT2ALMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | claimed |
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY | 2024-05-23 | — | — | US | disclosed |
| WO-2021077070-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | YALE UNIVERSITY (US) | 2021-04-22 | — | — | WO | disclosed |
| US-6297250-B1 | USEFUL FOR INHIBITING TRANSPORT OF NUCLEOSIDES OR PURINES ACROSS CELL MEMBRANES, THEREBY TO POTENTIATE THE ACTIVITY OF VARIOUS CYTOTOXIC ANTITUMOR DRUGS | NEWCASTLE UNIVERSITY VENTURES LIMITED (GB) | 2001-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166770-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF CELL-PENETRATING ANTIBODIES | SLC29A1, SLC29A2, SLC7A1 | PDE5A 521/4885CSF1R 1948/4885EGFR 1395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.